KDIGO 2017: CKD–mineral and bone disorder (CKD-MBD)
International KDIGO Current
KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of CKD-Mineral and Bone Disorder
Kidney Disease: Improving Global Outcomes CKD-MBD Update Work Group. Kidney Int Suppl. 2017;7:1–59
Summary checked against the source: 2026-11
The 2017 update revised parts of the 2009 KDIGO CKD-MBD guideline; the rest of 2009 stands. Grades: 1/2 with evidence A–D; NG = not graded.
At a glance
- Start monitoring calcium, phosphate, PTH and ALP from CKD G3a. [1C · p. 15]
- Decide on trends, looking at calcium, phosphate and PTH together, not single values or the Ca × P product. [1C, 2D · p. 15]
- Lower phosphate only when it's high (toward normal); avoid hypercalcaemia. [2C · p. 16]
- Restrict calcium-based binders in adults; no long-term aluminium binders. [2B, 1C · p. 16]
- Dialysis: keep iPTH at about 2–9 × the upper limit of normal. Treat with calcimimetics, calcitriol or vitamin D analogues, alone or combined. [2C, 2B · p. 16–17]
- Not on dialysis: don't use calcitriol routinely; reserve it for severe progressive hyperparathyroidism in G4–G5. [2C · p. 16]
- BMD testing now suggested to assess fracture risk if it will change treatment (reversed from 2009). [2B · p. 15]
Monitoring
| CKD stage | Calcium and phosphate | PTH | Alkaline phosphatase |
|---|---|---|---|
| G3a–G3b | Every 6–12 months | By baseline level and progression | |
| G4 | Every 3–6 months | Every 6–12 months | Every 12 months (more often if PTH high) |
| G5, G5D | Every 1–3 months | Every 3–6 months | Every 12 months (more often if PTH high) |
More often while treating or when abnormal. 25(OH)D may be measured, and deficiency corrected as for the general population. Adapted from KDIGO 2017 recommendations 3.1.1–3.1.3 [NG, 2C · p. 15]
Bone and vessels
- BMD (DXA) to assess fracture risk in G3a–G5D with CKD-MBD or osteoporosis risk factors, if it will change treatment. [2B · p. 15]
- Bone biopsy if knowing the type of renal osteodystrophy will change treatment. It's no longer required before antiresorptive drugs. [NG · p. 15, 19]
- PTH or bone-specific ALP can assess bone turnover: very high or low values predict it. Don't routinely measure collagen turnover markers. [2B, 2C · p. 15]
- Vascular calcification: a lateral abdominal X-ray or echocardiogram is a reasonable alternative to CT. Known calcification = highest cardiovascular risk. [2C, 2A · p. 15]
Treatment
Phosphate and calcium [p. 16]
- Base treatment on serial phosphate, calcium and PTH, considered together. [NG]
- Lower raised phosphate toward normal (not to keep it normal in G3–G4); treat only progressively or persistently high phosphate. [2C; NG]
- Avoid hypercalcaemia in adults; mild asymptomatic hypocalcaemia (e.g. on calcimimetics) can be tolerated. [2C]
- Restrict calcium-based phosphate binders. [2B]
- Limit dietary phosphate, considering its source (additives are absorbed most). [2D]
- Dialysis: dialysate calcium 1.25–1.50 mmol/L; increase dialytic phosphate removal for persistent hyperphosphataemia. [2C]
Recommended [p. 16]
- Avoid long-term aluminium-containing binders and aluminium-contaminated dialysate. [1C]
| PTH | Guidance | Grade |
|---|---|---|
| G3a–G5, not on dialysis | Optimal level unknown. If rising or persistently above normal, look for high phosphate, low calcium, high phosphate intake, vitamin D deficiency | 2C |
| Don't use calcitriol or analogues routinely; reserve for severe progressive hyperparathyroidism in G4–G5 | 2C; NG | |
| G5D | iPTH about 2–9 × upper limit of normal; act on marked changes within this range | 2C |
| Calcimimetic (cinacalcet), calcitriol or a vitamin D analogue, or calcimimetic + calcitriol/analogue | 2B | |
| Severe hyperparathyroidism not responding | Parathyroidectomy | 2B |
Adapted from KDIGO 2017 recommendations 4.2.1–4.2.5 [p. 16–17]
| Osteoporosis or high fracture risk | Treatment | Grade |
|---|---|---|
| G1–G2 | As for the general population | 1A |
| G3a–G3b with normal PTH | As for the general population | 2B |
| G3a–G5D with CKD-MBD abnormalities | Weigh the size and reversibility of the abnormalities and CKD progression; consider bone biopsy | 2D |
| Children with short stature | Growth hormone after correcting nutrition and CKD-MBD | 1A |
Adapted from KDIGO 2017 recommendations 4.3.1–4.3.4 [p. 17]
After kidney transplant
- Calcium and phosphate at least weekly until stable. [1B · p. 17]
- Later, monitor as for the same CKD stage, and correct vitamin D deficiency. [NG, 2C · p. 17]
- First 12 months, eGFR >30 and low BMD: consider vitamin D, calcitriol or alfacalcidol and/or antiresorptives. [2D · p. 18]
Clinical pearls
- CKD-MBD triad: abnormal biochemistry (Ca, PO₄, PTH, vitamin D), bone disease (renal osteodystrophy), vascular calcification.
- Secondary hyperparathyroidism: high phosphate and low calcitriol drive PTH up. Tertiary: autonomous PTH with high calcium after long-standing disease.
- Calcimimetics lower PTH without raising calcium or phosphate; watch for hypocalcaemia.
- Dialysis PTH target 2–9 × ULN.
Classes and levels of evidence
How KDIGO CKD-MBD 2017 grades its recommendations. Adapted from KDIGO CKD-MBD 2017 grading system [p. 1–59]. Hover over any class or level cited on this page to see what it means.
| Grade | Meaning | Wording used |
|---|---|---|
| 1A | Level 1, strong: we recommend. Most people would want this course of action; quality A (high): we are confident that the true effect is close to the estimate | |
| 1B | Level 1, strong: we recommend. Most people would want this course of action; quality B (moderate): the true effect is likely close to the estimate but may be substantially different | |
| 1C | Level 1, strong: we recommend. Most people would want this course of action; quality C (low): the true effect may be substantially different | |
| 1D | Level 1, strong: we recommend. Most people would want this course of action; quality D (very low): the estimate is very uncertain and often far from the truth | |
| 2A | Level 2, weak: we suggest. Most people would want it, but many would not; quality A (high): we are confident that the true effect is close to the estimate | |
| 2B | Level 2, weak: we suggest. Most people would want it, but many would not; quality B (moderate): the true effect is likely close to the estimate but may be substantially different | |
| 2C | Level 2, weak: we suggest. Most people would want it, but many would not; quality C (low): the true effect may be substantially different | |
| 2D | Level 2, weak: we suggest. Most people would want it, but many would not; quality D (very low): the estimate is very uncertain and often far from the truth | |
| Practice point | Ungraded expert advice where a systematic review was not done | |
| Not graded | Ungraded statement based on common sense, or on a topic with no basis for grading evidence |
KDIGO grades each recommendation by strength (1 = "we recommend", 2 = "we suggest") and quality of evidence (A high, B moderate, C low, D very low), written together as 1B, 2C and so on. Practice points (PP) are ungraded expert advice where no systematic review was done. Older KDIGO guidelines also have "Not Graded" statements.